News & Updates

Treatment with low-dose spironolactone results in reduced albuminuria without causing hyperkalaemia in patients with type 2 diabetes (T2D), reports a study.

Faecal microbiota transplantation helps reduce abdominal bloating but not the overall symptoms in patients with irritable bowel syndrome (IBS), according to a small study.

The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.